OLX 702A
Alternative Names: OLX-702A; OLX-75016Latest Information Update: 15 Feb 2024
At a glance
- Originator OliX Pharmaceuticals
- Class Amides; Amino sugars; Drug conjugates; Hepatoprotectants; Pyrrolidines; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 13 Feb 2024 Phase-I clinical trials in Non-alcoholic steatohepatitis in Australia (Parenteral)
- 22 Dec 2023 Olix Pharmaceuticals receives approval from the Alfred Human Research Ethics Committee (HREC) for phase I trial of OLX 702A in Non-alcohol steatohepatitis (NASH)
- 22 Dec 2023 Olix Pharmaceuticals plans phase I trial of OLX 702A in Non-alcohol steatohepatitis (NASH)